SEARCH

SEARCH BY CITATION

References

  • 1
    Thompson WW, Shay DK, Weintraub E et al . Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179186.
  • 2
    Thompson WW, Shay DK, Weintraub E et al . Influenza-associated hospitalizations in the United States. JAMA 2004; 292:13331340.
  • 3
    Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007; 4:917.
  • 4
    Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:11591169.
  • 5
    Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46:10781084.
  • 6
    Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25:68526862.
  • 7
    Ansaldi F, Bacilieri S, Banfi F et al . Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004–2005 influenza vaccine against drifted viruses. Clin Vaccine Immunol 2006; 13:162164.
  • 8
    Ansaldi F, Bacilieri S, Durando P et al . Cross-protection by MF59trade mark-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26:15251529.
  • 9
    De Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61:9499.
  • 10
    Del Giudice G, Hilbert AK, Bugarini R et al . An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24:30633065.
  • 11
    Kojimahara N, Maeda A, Kase T, Yamaguchi N. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 2006; 24:59665969.
  • 12
    Palese P. Influenza: old and new threats. Nat Med 2004; 10:S82S87.
  • 13
    Peiris JS, De Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007; 20:243267.
  • 14
    Potter CW. A history of influenza. J Appl Microbiol 2001; 91:572579.
  • 15
    Bridges CB, Lim W, Hu-Primmer J et al . Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997–1998. J Infect Dis 2002; 185:10051010.
  • 16
    Nicholson KG, Colegate AE, Podda A et al . Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:19371943.
  • 17
    Ungchusak K, Auewarakul P, Dowell SF et al . Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333340.
  • 18
    World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza (H5n1) Reported to WHO. Geneva: World Health Organization, 2008. Available at: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_04_08/en/index.html (accessed 15 April 2008) (GENERIC).
  • 19
    World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2008; 11:15151521.
  • 20
    Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med 2002; 76:105115.
  • 21
    Tumpey TM, Basler CF, Aguilar PV et al . Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005; 310:7780.
  • 22
    World Health Organization. Responding to the Avian Influenza Pandemic Threat: Recommended Strategic Actions, 2005. Available at: http://www.who.int/csr/resouces/publications/influenza/WHO_CDS_CSR_GIP-05-8-EN.pdf (accessed 17 March 2008) (GENERIC)
  • 23
    Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:13431351.
  • 24
    Bresson JL, Perronne C, Launay O et al . Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:16571664.
  • 25
    Leroux-Roels I, Borkowski A, Vanwolleghem T et al . Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine. Lancet 2007; 370:580589.
  • 26
    Lin J, Zhang J, Dong X et al . Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991997.
  • 27
    Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197203.
  • 28
    O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6:699710.
  • 29
    Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008; 180:54025412.
  • 30
    Mosca F, Tritto E, Muzzi A et al . Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008; 105:1050110506.
  • 31
    Huckriede A, Bungener L, Stegmann T et al . The virosome concept for influenza vaccines. Vaccine 2005; 23(Suppl 1):S2638.
  • 32
    Belshe RB, Newman FK, Wilkins K et al . Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25:67556763.
  • 33
    O’Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin Pharmacol Ther 2007; 82:740744.
  • 34
    Cataldo DM, Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 1997; 15:17101715.
  • 35
    Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996; 14:478484.
  • 36
    Minutello M, Senatore F, Cecchinelli G et al . Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17:99104.
  • 37
    De Donato S, Granoff D, Minutello M et al . Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17:30943101.
  • 38
    Gasparini R, Pozzi T, Montomoli E et al . Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135140.
  • 39
    Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19:26732680.
  • 40
    Del Giudice G, Fragapane E, Bugarini R et al . Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 2006; 13:10101013.
  • 41
    Schultze V, D’Agosto V, Wack A, et al . Safety of MF59 adjuvant. Vaccine 2008; 26:32093222.
  • 42
    Haber P, DeStefano F, Angulo FJ et al . Guillain-Barre syndrome following influenza vaccination. JAMA 2004; 292:24782481.
  • 43
    Corey L, Langenberg AG, Ashley R et al . Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282:331340.
  • 44
    Cunningham CK, Wara DW, Kang M et al . Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis 2001; 32:801807.
  • 45
    Heineman TC, Clements-Mann ML, Poland GA et al . A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999; 17:27692778.
  • 46
    Langenberg AG, Burke RL, Adair SF et al . A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med 1995; 122:889898.
  • 47
    Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002; 21:133138.
  • 48
    Stephenson I, Nicholson KG, Colegate A et al . Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:16871693.
  • 49
    Gambotto A, Barratt-Boyes SM, De Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008; 371:14641475.
  • 50
    Stephenson I, Bugarini R, Nicholson KG et al . Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:12101215.
  • 51
    Banzhoff A, Montomoli E, Hilbert AK et al . MF59-adjuvanted vaccine is well tolerated and effective at low doses, offering a suitable vaccine for pre-pandemic vaccination programs. Options for the Control of Influenza VI 2007, Toronto, Canada, 17–23 June 2007.
  • 52
    Sambhara S, Kurichh A, Miranda R et al . Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 2001; 211:143153.
  • 53
    Brauer V, Laghi-Pasini F, Capecchi PL et al . Priming for pandemic influenza: Antigen-sparing MF59-adjuvanted A/H5N1 vaccine induces immunological memory and shows cross-reactive potential in adults including the elderly. 13th International Congress on Infectious Diseases 2008, Kuala Lumpur, Malaysia, 19–22 June 2008.
  • 54
    Stephenson I, Nicholson KG, Hoschler K et al . Antigenically distinct MF59 adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:16311633.
  • 55
    Galli G, Castellino F, Bardelli M et al . MF59-adjuvanted H5N1 subunit vaccine induces a large and stable pool of memory B cells. Third European Influenza Conference 2008. Vilamoura, Portugal. 1719 September 2008.
  • 56
    Castellino F, Galli G, Borgogni E et al . MF59-adjuvanted H5N1 subunit vaccine induces a high frequency of Th1 effector/memory CD4 T-cells which persist over time. Third European Influenza Conference 2008. Vilamoura, Portugal. 1417 September 2008.